Full Lp(a)HORIZON Trial Results Show No Benefit of Pelacarsen for Cardiovascular Risk Reduction

The complete findings from the Lp(a)HORIZON trial, published in NEJM Evidence and presented at the American Heart Association (AHA) 2026 Scientific Sessions, indicate that pelacarsen did not reduce major adverse cardiovascular events in patients with pre-existing cardiovascular disease and elevated lipoprotein(a) levels. The trial also raised some safety concerns, including higher rates of drug-related adverse events, discontinuations, constitutional symptoms, and hypersensitivity reactions in the active treatment group.

Context

The Lp(a)HORIZON trial was designed to assess the effectiveness of pelacarsen in reducing major adverse cardiovascular events among patients with high lipoprotein(a) levels. Lipoprotein(a) is a known risk factor for cardiovascular disease, and previous studies suggested that targeting it could be beneficial. The trial's results were presented at the American Heart Association 2026 Scientific Sessions and published in NEJM Evidence, highlighting their relevance to ongoing cardiovascular research.

Why it matters

The findings from the Lp(a)HORIZON trial are significant as they challenge the efficacy of pelacarsen, a treatment aimed at reducing cardiovascular risks in patients with elevated lipoprotein(a). This trial's results may influence treatment guidelines and patient management strategies for those with pre-existing cardiovascular conditions. Understanding the limitations of pelacarsen is crucial for healthcare providers in making informed decisions about patient care.

Implications

The lack of benefit from pelacarsen in reducing cardiovascular events may lead to a reevaluation of treatment options for patients with high lipoprotein(a). Patients currently on pelacarsen may need to discuss alternative therapies with their healthcare providers. Additionally, the trial's safety concerns could prompt increased caution in prescribing this medication, affecting pharmaceutical companies and their future research directions.

What to watch

In the near term, healthcare professionals will likely scrutinize the trial's findings to reassess the use of pelacarsen in clinical practice. Further discussions at medical conferences and in scientific publications may emerge as experts analyze the implications of the results. Monitoring any updates regarding alternative treatments for elevated lipoprotein(a) levels will also be important.